TGen Drug Development   Report issue

Foundation Phase 1 Phase 2
Founded: Phoenix AZ United States (2003)

Organization Overview

First Clinical Trial
2007
NCT00528047
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

TGen Clinical Research Service at Scottsdale Healthcare | TGen Clinical Research Services at Scottsdale Healthcare | TGEN Clinical Research Services at Scottsdale Healthcare | Translational Genomics Research Institute | Translational Genomics Research Institute (TGen) An Affiliate of City of Hope

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Headache (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Post-Traumatic Headache (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial APIs: 19